REXTOVY Drug Patent Profile
✉ Email this page to a colleague
When do Rextovy patents expire, and what generic alternatives are available?
Rextovy is a drug marketed by Amphastar Pharms Inc and is included in one NDA.
The generic ingredient in REXTOVY is naloxone hydrochloride. There are twelve drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rextovy
A generic version of REXTOVY was approved as naloxone hydrochloride by HOSPIRA on September 24th, 1986.
Summary for REXTOVY
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | REXTOVY at DailyMed |
Pharmacology for REXTOVY
Drug Class | Opioid Antagonist |
Mechanism of Action | Opioid Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for REXTOVY
US Patents and Regulatory Information for REXTOVY
REXTOVY is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting REXTOVY
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amphastar Pharms Inc | REXTOVY | naloxone hydrochloride | SPRAY, METERED;NASAL | 208969-001 | Mar 7, 2023 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |